Zobrazeno 1 - 10
of 822
pro vyhledávání: '"B. Livingston"'
Autor:
Megan H. Jagosky, Colin J. Anderson, James T. Symanowski, Nury M. Steuerwald, Carol J. Farhangfar, Emily A. Baldrige, Jennifer H. Benbow, Michael B. Livingston, Joshua C. Patt, Will A. Ahrens, Jeffrey S. Kneisl, Edward S. Kim
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7029-7038 (2023)
Abstract Purpose Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options. Experimental Design Patients treated at Levine Cancer Institut
Externí odkaz:
https://doaj.org/article/7e061913e58d4d3093d3ab4b289a48b5
Autor:
Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1532-1539 (2023)
Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm,
Externí odkaz:
https://doaj.org/article/124378635bd247fb9b2242a52cc12063
Autor:
Megan H, Jagosky, Colin J, Anderson, James T, Symanowski, Nury M, Steuerwald, Carol J, Farhangfar, Emily A, Baldrige, Jennifer H, Benbow, Michael B, Livingston, Joshua C, Patt, Will A, Ahrens, Jeffrey S, Kneisl, Edward S, Kim
Publikováno v:
Cancer Medicine. 12:7029-7038
Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options.Patients treated at Levine Cancer Institute with DDLPS were identified. Next gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987f34a322de0cc7dffc986d5ebe7bf4
https://doi.org/10.1002/cam4.5502
https://doi.org/10.1002/cam4.5502
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael B. Livingston, Anthony D. Elias, Tony Philip, Michael Chen, Margaret von Mehren, Sant P. Chawla, Scott H. Okuno, Sergey Yurasov, Brian A. Van Tine, Claire F. Verschraegen, Robert G. Maki, Steven Attia, G Chet Bohac, Kristen N. Ganjoo, Hailing Lu, Richard F. Riedel, Mark Agulnik, Edwin Choy, Vicki L. Keedy, Adam Yakovich, Seth M. Pollack
Publikováno v:
Journal of Clinical Oncology. 40:1291-1300
PURPOSE CMB305 is a heterologous prime-boost vaccination regimen created to prime NY-ESO-1–specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. This open-label randomized phase II trial was designed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d95353bef9451bc8ef7cc9448c5326
https://doi.org/10.1200/jco.20.03452
https://doi.org/10.1200/jco.20.03452
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Treatment Emergent Adverse Events Attributed to Pembrolizumab, Any Grade.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf832be93579c2f32e46091b3577a41b
https://doi.org/10.1158/1078-0432.22483110.v1
https://doi.org/10.1158/1078-0432.22483110.v1
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
All Treatment Emergent Adverse Events Regardless of Causality, Any Grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7850331292f3a8df2d0b89871ed91528
https://doi.org/10.1158/1078-0432.22483116.v1
https://doi.org/10.1158/1078-0432.22483116.v1
Autor:
David A. Mankoff, Kenneth A. Krohn, Jeanne M. Link, Philip H. Petra, Robert B. Livingston, Thomas J. Lawton, Georgiana K. Ellis, Jennifer M. Specht, Julie R. Gralow, Erin K. Schubert, Lanell M. Peterson, Brenda F. Kurland, Hannah M. Linden
Purpose: To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy.Experimental Design: The ER has been a highly successful target for breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223b35d88cbc7b10d10f0100295d7c2e
https://doi.org/10.1158/1078-0432.c.6519107
https://doi.org/10.1158/1078-0432.c.6519107
Autor:
David A. Mankoff, Kenneth A. Krohn, Jeanne M. Link, Philip H. Petra, Robert B. Livingston, Thomas J. Lawton, Georgiana K. Ellis, Jennifer M. Specht, Julie R. Gralow, Erin K. Schubert, Lanell M. Peterson, Brenda F. Kurland, Hannah M. Linden
PDF file - 85K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb0f3cbc34fdddf1f57b60213116294
https://doi.org/10.1158/1078-0432.22442366
https://doi.org/10.1158/1078-0432.22442366
Autor:
Edward S. Kim, Jeffrey S. Kneisl, Joshua C. Patt, Colin J. Anderson, Nury M. Steuerwald, James T. Symanowski, Xhevahire Begic, Emily A. Baldrige, Deirdre M. Maxwell, David M. Foureau, Carol J. Farhangfar, Jennifer H. Benbow, William A. Ahrens, Myra M. Robinson, Megan H. Jagosky, Michael B. Livingston
Purpose:Doxorubicin is standard therapy for advanced soft-tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity and tolerab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20971f5acf9784dd02c761e4e33482dc
https://doi.org/10.1158/1078-0432.c.6531075.v1
https://doi.org/10.1158/1078-0432.c.6531075.v1